Source comparison
Tesamorelin Peptide: Mechanism Comparison
Understanding how tesamorelin peptide compares to other growth hormone modulators clarifies its unique therapeutic niche. The table below contrasts mechanism, receptor target, and metabolic outcomes for tesamorelin, direct GH, and ghrelin receptor agonists. Te
This comparison does not assign a generated winner or score.
- Understanding how tesamorelin peptide compares to other growth hormone modulators clarifies its unique therapeutic niche. The table below contrasts mechanism, receptor target, and metabolic outcomes for tesamorelin, direct GH, and ghrelin receptor agonists.
- Tesamorelin (GHRH analog)
- Stimulates pituitary GH secretion in physiological pulses
- GHRH type 1 receptor (pituitary somatotrophs)
- High. VAT reduction 15–18% at 26 weeks, minimal subcutaneous loss
- Neutral to slight improvement. Maintains insulin sensitivity across 26 weeks in clinical trials
- 38–47 minutes
- Best option for visceral adiposity without glucose dysregulation; requires daily subcutaneous injection; effects reverse within 26 weeks of cessation
- Recombinant Growth Hormone (exogenous GH)
- Direct GH replacement, bypassing pituitary
- Growth hormone receptor (liver, muscle, adipose tissue)
- Moderate. Reduces total body fat 5–10%, not VAT-selective
- Negative. Causes dose-dependent insulin resistance and fasting glucose elevation within 8–12 weeks
- 2.5–3.5 hours
- Broader anabolic effects but significant metabolic risk; supraphysiological dosing required; not suitable for subjects with pre-diabetes
- Ipamorelin (ghrelin mimetic)
- Stimulates GH release via ghrelin pathway without cortisol or prolactin co-secretion
- Ghrelin receptor (GHSR-1a, pituitary and hypothalamus)
- Low. General lipolysis without VAT preference
- Neutral. Maintains baseline insulin sensitivity
- 2 hours
- Synergistic with tesamorelin for combined GHRH and ghrelin pathway activation; shorter half-life requires multiple daily doses; less clinical evidence than tesamorelin
- Sermorelin (GHRH analog, shorter)
- Stimulates pituitary GH secretion but with rapid degradation
- GHRH type 1 receptor
- Moderate. Less potent than tesamorelin due to shorter half-life and lack of chemical modification
- Neutral
- 10–20 minutes
- Requires multiple daily doses; lower cost but inferior pharmacokinetics; clinical data sparse compared to tesamorelin
- MK-677 (oral ghrelin mimetic)
- Oral ghrelin receptor agonist, continuous GH and IGF-1 elevation
- Ghrelin receptor (GHSR-1a)
- Low. Non-selective fat loss
- Mixed. Increases appetite and may worsen glycemic control in susceptible individuals
- 24 hours
- Convenient oral dosing but lacks pulsatility; chronic elevation may lead to receptor downregulation; not FDA-approved
- Tesamorelin's therapeutic window sits between the specificity of direct intervention (exogenous GH) and the physiological elegance of endogenous pathway modulation. For research applications targeting visceral adiposity without metabolic side effects, tesamorelin remains the gold standard.